Just – Evotec Biologics has expanded its relationship with Advanced BioScience Laboratories (ABL), a global CDMO serving the US Government and biopharmaceutical industry.
Abzena, an end-to-end CDMO for biologics and bioconjugates, has launched AbZelect and AbZelectPRO cell line development (CLD) platforms to accelerate cell lie production for manufacturing antibodies and recombinant proteins.
The proof-of-concept trial, dubbed IRIS-RA, is the first to investigate a treatment for rheumatoid arthritis that blocks a protein called neonatal Fc receptor (FcRn).
The antibody drug nipocalimab, developed by the Janssen Pharmaceutical...
Memo Therapeutics, a biotech company developing therapeutic antibodies, has announced that the US Food and Drug Administration (FDA) has granted Fast Track designation to AntiBKV.
Hansa Biopharma and Genethon have entered a research and development collaboration to test imlifidase as a gene therapy treatment in patients with pre-existing neutralizing antibodies.
The clinical stage biopharmaceutical company will use its RADR artificial intelligence (AI) and machine learning platform to transform the cost, pace, and timeline of oncology drug discovery and development.
BigHat Biosciences, a US biotech with a machine learning-guided antibody discovery and development platform, has announced a collaboration with Merck to apply its technology to design candidates for up to three drug discovery programs.
AbbVie will acquire DJS Antibodies Ltd, a privately-held UK-based biotechnology company dedicated to discovering and developing antibody medicines that target difficult-to-drug disease-causing proteins.
AstraZeneca's long-acting antibody combination Evusheld has been approved in Japan for both prevention (pre-exposure prophylaxis) and treatment of symptomatic disease caused by SARS-CoV-2 infection: marking the first global marketing approval of...
BioNTech and Genmab are expanding a global collaboration to develop and commercialize novel immunotherapies for the treatment of cancer patients: with the first monospecific antibody candidate expected to enter clinical trials by the end of the year.
People with HIV who began taking antiretroviral therapy (ART) in the early stages of infection achieved a lengthy period of HIV suppression without ART after receiving two broadly neutralizing anti-HIV antibodies (bNAbs), according to a study published...
Northway Biotech, a contract development and manufacturing organization (CDMO) based out of Vilnius, Lithuania, is set to open a facility in Boston, US.
Chinese companies, Biocytogen Pharmaceuticals and CtM Biotech Co Ltd, are collaborating on the development of antibody drugs against intracellular tumor-associated antigens.
Spirulina has been converted into a biomanufacturing platform that offers a way to rapidly produce mass quantities of biologic drugs for common diseases that currently lack effective treatments, say US developers.
Biomunex Pharmaceuticals, a French company focused on the discovery and development of bi- and multi-specific antibodies, sees its BiXAb5 project receive nearly €3m (US$3.5m) in the form of a grant from the French government.
AstraZeneca's AZD7442, a long acting antibody (LAAB) combination, achieved a statistically significant reduction in severe COVID-19 or death compared to placebo in non-hospitalised patients with mild-to-moderate symptomatic COVID-19.
A new partnership promises improved biomanufacturing processes for gene therapies; the goal is to support the sector in scaling up through more efficient, cost-effective processes.
The mRNA vaccine developed by Pfizer and BioNTech generates far higher levels of antibodies against the coronavirus than Sinovac’s inactivated virus prophylactic, according to a study.
REGEN-COV (casirivimab with imdevimab) has been shown to reduce the risk of symptomatic SARS-CoV-2 infections by 81%, in a Phase 3 study among household contacts of infected individuals.
Tokyo headquartered, Fujifilm Corporation, has announced a new US$2bn (£1.4bn/€1.5bn) investment to establish a new large-scale biopharma site in the US.
Emerging biotech, NanoSyrinx, has announced the closing of a pre-seed financing round to continue developing its ‘nanosyringes’, a selective non-viral peptide and protein delivery system.
Two leading clinical research organizations (CROs) say they have identified neutralizing antibodies with great potential for monoclonal antibody treatment.
As part of a cost-savings restructure, Epirus is selling the assets from its $14m acquisition of Bioceros last September to its biosimilars partner Polpharma.
